Skip to main content

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of KRN23 in Adult Patients with X-linked Hypophosphatemia (XLH)¿

Clinical Trial Grant
Duke Scholars

Administered By

School of Medicine

Awarded By

Ultragenyx Pharmaceutical

Start Date

September 15, 2015

End Date

May 31, 2019
 

Administered By

School of Medicine

Awarded By

Ultragenyx Pharmaceutical

Start Date

September 15, 2015

End Date

May 31, 2019